197 results
424B3
ATHXQ
Athersys, Inc / New
4 Dec 23
Prospectus supplement
7:27am
that is focused primarily in the field of regenerative medicine. Our MultiStem® (invimestrocel) cell therapy, a patented and proprietary allogeneic stem cell
8-K
EX-99.1
ATHXQ
Athersys, Inc / New
11 Oct 23
Entry into a Material Definitive Agreement
9:27am
) – Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications … MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability
8-K
EX-99.1
pnl4zpxr1aapj66sr
3 Oct 23
Other Events
4:41pm
8-K
EX-99.1
n8xgg648tgu
2 Oct 23
Athersys Director Jane Wasman Appointed Board Chair
5:05pm
424B3
4iuhia f7
25 Sep 23
Prospectus supplement
4:36pm
424B4
efkve n8ao2o8biv
21 Aug 23
Prospectus supplement with pricing info
2:36pm
424B3
fsva7vz5m7sm7vvl0j
8 Jun 23
Prospectus supplement
10:28am
424B3
xbehd va2
8 Jun 23
Prospectus supplement
10:28am
8-K
EX-99.1
ydsimff
23 May 23
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
fkla0p
18 May 23
Athersys Reports First Quarter 2023 Financial Results and Provides Business Update
10:13am